Eddie Cliff, Haematology Registrar at Peter MacCallum Cancer Centre, shared a post on X about a paper he co-authored with colleagues published in JNCI: Journal of the National Cancer Institute:
“Just out in JNCI: Journal of the National Cancer Institute, we review 20 years of RCTs in myeloma for lessons in drug development.
Surprisingly, head-to-head trials were as likely to be successful as add-on trials.”
Samer Al Hadidi, Associate Professor at UAMS – University of Arkansas for Medical Sciences, shared this post, adding:
“Optimizing oncology drug development: systematic review of 22 years of myeloma randomized controlled trials.
- Just 35% of successful trials led to FDA approval
- meeting endpoints ≠ regulatory approval.”
Title: Optimizing oncology drug development: systematic review of 22 years of myeloma randomized controlled trials
Authors: Maria Mainou, Muatassem Alsadhan, Kalliopi Tsapa, Alissa Visram, Hira Mian, Rakesh Popat, Elias K Mai, Rajshekhar Chakraborty, Samer Al Hadidi, Meera Mohan, Aniko Szabo, Oliver Van Oekelen, Edward R Scheffer Cliff, and Ghulam Rehman Mohyuddin.
You can read the Full Article in JNCI: Journal of the National Cancer Institute.
More posts featuring Eddie Cliff.
